Overview

First-in-human Evaluation of EAAT2 PET Tracer in Healthy and Alzheimer's Diseased Brain

Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a first in human study that will assess the safety and diagnostic performance of [18F]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer disease.
Phase:
Early Phase 1
Details
Lead Sponsor:
David Wilson
Collaborator:
Rio pharmaceuticals Inc.